A Bayesian phase I/II platform design with survival efficacy endpoint for dose optimization
Statistical Methods in Medical Research: An International Review Journal
Published online on May 14, 2026
Abstract
Statistical Methods in Medical Research, Ahead of Print.
Motivated by a real-world drug development program, we propose a Bayesian phase I/II platform design to co-develop therapies with time-to-event efficacy endpoint (BPCT). We jointly model the binary toxicity outcome and the time-to-event efficacy outcome, ...
Motivated by a real-world drug development program, we propose a Bayesian phase I/II platform design to co-develop therapies with time-to-event efficacy endpoint (BPCT). We jointly model the binary toxicity outcome and the time-to-event efficacy outcome, ...